Guide

Buy-and-bill: J-codes, margins, and the risk of a fridge

Summary

Buy-and-bill means your practice purchases a physician-administered drug from a distributor, administers it, and bills the payer for both the drug (an HCPCS J-code) and a separate administration code. Reimbursement for the drug is typically the payer's contracted rate minus your acquisition cost, so the margin depends on your purchase price relative to the fee schedule — and every unbilled or expired vial is a direct loss, not a paper one.

By Gale Editorial · Updated 2026-07-26. Every figure cited to a dated source. How we write.

What buy-and-bill actually is

Buy-and-bill is the model where your practice purchases a physician-administered drug directly from a distributor or specialty pharmacy, holds it in inventory, administers it to the patient, and then bills the payer for the drug itself using its HCPCS J-code — separately from the administration code that pays for the clinical work of giving it 1Ref 1American Medical Association (2026).CPT® (Current Procedural Terminology).That CPT defines the administration procedure codes billed separately from a drug's J-code. This is different from a patient-obtained drug billed through a retail pharmacy, where your practice never purchases or holds the product. Buy-and-bill puts your practice on the hook for the purchase price up front, with reimbursement arriving only after the claim is billed and adjudicated — weeks after the money left your account.

Two separate codes, two separate payments

Every buy-and-bill claim carries at least two line items: the J-code for the drug itself, and a CPT administration code for the service of giving it — an injection, infusion, or other administration procedure. These are billed together on the same claim but priced independently: the payer's Medicare Physician Fee Schedule lookup returns a separate payment amount and RVU set for the administration code, distinct from whatever the drug's J-code pays 2Ref 2Centers for Medicare & Medicaid Services (2026).Physician Fee Schedule Search.The lookup method for checking a J-code's and an administration code's current payment amount before stocking a drug. Mixing this up — assuming the administration code's payment covers the drug, or vice versa — is a common source of underbilled claims in a solo office new to this workflow.

Where the margin comes from, and where it disappears

The drug reimbursement on a buy-and-bill claim is set by the payer's fee schedule for that J-code, not by what you actually paid the distributor — so your margin is the spread between your acquisition cost and the payer's allowable, and that spread moves with every price change from either side. A distributor price increase without a corresponding fee schedule increase compresses the margin without you doing anything wrong. The margin also assumes every purchased unit gets billed: a vial that expires unused, is wasted mid-dose, or is administered to a patient later found ineligible is a straight loss with no offsetting reimbursement, which is the structural risk of holding inventory that a pharmacy-dispensed model doesn't carry.

Checking what a J-code actually pays before you stock it

Before adding a new buy-and-bill drug to your practice, look up its J-code in the same public Medicare Physician Fee Schedule search tool you'd use for any other code — it returns the current payment amount for your locality alongside the RVUs and payment indicators 2Ref 2Centers for Medicare & Medicaid Services (2026).Physician Fee Schedule Search.The lookup method for checking a J-code's and an administration code's current payment amount before stocking a drug. Compare that number against your actual quoted acquisition cost from the distributor, not a list price, since the two can diverge meaningfully. If the spread is thin or negative at your quoted cost, that's a decision point before the vial is in your fridge, not after.

Watch for bundling and unit-cap edits on the same claim

Buy-and-bill claims are exactly the kind that trip NCCI procedure-to-procedure edits and unit caps: an administration code billed alongside an unrelated E/M visit on the same date, or units of the drug's J-code exceeding its published Medically Unlikely Edit cap, can both deny even when the clinical work was appropriate 3Ref 3Centers for Medicare & Medicaid Services (2026).NCCI for Medicare.That NCCI procedure-to-procedure edits can bundle an administration code with another same-date service4Ref 4Centers for Medicare & Medicaid Services (2026).Medically Unlikely Edits.That a J-code's billed units are capped by a published MUE regardless of clinical need. Checking the current NCCI edit file for your J-code and administration code pair 3Ref 3Centers for Medicare & Medicaid Services (2026).NCCI for Medicare.That NCCI procedure-to-procedure edits can bundle an administration code with another same-date service, and the MUE for the J-code's unit count 4Ref 4Centers for Medicare & Medicaid Services (2026).Medically Unlikely Edits.That a J-code's billed units are capped by a published MUE regardless of clinical need, before submitting catches most of this in advance rather than in a resubmission cycle.

Where solo practices most often stumble

The failure mode in a solo office is rarely the billing itself — it's the inventory and pricing decisions made before a single claim goes out, decisions that compound quietly until a slow quarter or a fee schedule change exposes them all at once. The four patterns below account for most of the margin a solo buy-and-bill practice loses.

Buying more inventory than the practice's actual patient volume supports, which turns the margin calculation into an expiration-date race.
Not tracking waste separately from what was administered, so a partial-vial loss goes unbilled and untracked instead of documented for the payer's waste-billing modifier where one applies.
Assuming a payer's fee schedule rate holds indefinitely — it's re-set with the same rulemaking cycle as the rest of the Physician Fee Schedule, so a margin that worked last year isn't guaranteed this year without rechecking 2Ref 2Centers for Medicare & Medicaid Services (2026).Physician Fee Schedule Search.The lookup method for checking a J-code's and an administration code's current payment amount before stocking a drug.
Treating the drug purchase like any other supply expense rather than as inventory carrying real financial risk between purchase and reimbursement.

Common questions

It depends on whether your patient volume for that specific drug is predictable enough to avoid expired or wasted inventory, since the margin only materializes if nearly every purchased unit gets administered and billed. A practice administering the drug to one or two patients a month is carrying inventory risk that a higher-volume practice absorbs more easily on the same margin.

The J-code reimburses the drug product itself, priced against the payer's fee schedule; the administration code reimburses the clinical service of giving it, priced independently with its own RVUs. Both must be billed correctly and separately — one does not substitute for the other, and omitting either line item underbills the claim.

Some payers recognize a waste-billing modifier for a single-use vial where documented unused product had to be discarded, but this is payer- and drug-specific rather than automatic. Checking the specific payer's policy for that J-code before assuming waste is billable avoids a denial on a claim you expected to recover.

Compare the drug's current J-code payment from the Medicare Physician Fee Schedule lookup against your actual quoted acquisition cost from the distributor, then weigh that spread against your realistic patient volume and expiration timeline for that product. A thin margin combined with unpredictable volume is the combination most likely to turn a stocked drug into a loss.

Buy-and-bill itself isn't a separate enrollment category — it uses your existing billing infrastructure and NPI — but purchasing and storing a controlled or specialty drug may carry its own state and DEA requirements depending on the specific product. Those requirements sit outside the billing mechanics and are worth confirming per drug before adding it to your buy-and-bill list.

Run your practice on Gale

The software is free. Gale earns one flat 3.5% all-in per paid transaction — only on transactions that actually pay. No subscription, no setup fee, no network cut.

Start or manage a practice →

References

1.American Medical Association (2026). CPT® (Current Procedural Terminology). American Medical Association (AMA). link ✓That CPT defines the administration procedure codes billed separately from a drug's J-code
2.Centers for Medicare & Medicaid Services (2026). Physician Fee Schedule Search. Centers for Medicare & Medicaid Services (CMS). link ✓The lookup method for checking a J-code's and an administration code's current payment amount before stocking a drug
3.Centers for Medicare & Medicaid Services (2026). NCCI for Medicare. Centers for Medicare & Medicaid Services (CMS). link ✓That NCCI procedure-to-procedure edits can bundle an administration code with another same-date service
4.Centers for Medicare & Medicaid Services (2026). Medically Unlikely Edits. Centers for Medicare & Medicaid Services (CMS). link ✓That a J-code's billed units are capped by a published MUE regardless of clinical need

https://www.gale.care/for-providers/fs-drug-jcode-buy-bill · 4 sources. Competitor details are cited to dated public sources and maintained as they change; figures are estimates, not commitments. Synthetic demonstration.

← Back to for providers